Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of *Plasmodium falciparum* in Europe: sentinel data from TropNetEurop

Ole Wichmann*†1, Tomas Jelinek1, Gabriele Peyerl-Hoffmann3, Nikolai Mühlberger1, Martin P Grobusch2,4, Joaquim Gascon8, Alberto Matteelli10, Christoph Hatz11, Hermann Laferl12, Marco Schulze5, Gerd Burchard1,6, Saraiva da Cunha14, Jiøi Beran15, Paul McWhinney16, Herwig Kollaritsch13, Peter Kern7, Juan Cuadros9, Michael Alifrangis17, Ida Gjørup17 and the European Network on Surveillance of Imported Infectious Diseases (TropNetEurop)

Address: 1Institute of Tropical Medicine. Charité, Humboldt University, Berlin, Germany, 2Department of Medicine (Infectious Diseases), University of Munich, Germany, 3Institut für Tropenmedizin, Eberhard-Karls-Universität Tübingen, Germany, 4Städtische Kliniken "St. Georg", 5Klinik für Innere Medizin, Leipzig, Germany, 6Bernhard-Nocht-Institute for Tropical Medicine, University of Hamburg, Germany, 7Sektion Infektiologie und Klinische Immunologie, Universität Ulm, Ulm, Germany, 8Secció Medicina Tropical, Hospital Clinic, IDIBAPS, Barcelona, Spain, 9Department of Clinical Microbiology and Parasitology, Hospital Príncipe de Asturias, Madrid, Spain, 10Clinica di Malattie Infettive e Tropicali, Università di Brescia, Italy, 11Swiss Tropical Institute, Basel, Switzerland, 12Kaiser-Franz-Josef-Spital der Stadt Wien, 13Abteilung für spezifische Prophylaxe und Tropenmedizin am Institut für Pathophysiologie, University of Vienna and Kaiser-Franz-Josef-Spital der Stadt Wien, Vienna, Austria, 14Consulta de Medicina do Viajante, Departamento de Doenças Infecciosas, Hospital Universitário, Coimbra, Portugal, 15Department of Infectious Diseases, University Hospital, Hradec Kralove, Czech Republic, 16Bradford Royal Infirmary, Infection and Tropical Medicine, Bradford, United Kingdom and 17Department of Infectious Diseases, University Hospital and Centre of Medical Parasitology, Panum Institute, University of Copenhagen, Denmark

Email: Ole Wichmann* - ole.wichmann@charite.de; Tomas Jelinek - jelinek@bbges.de; Gabriele Peyerl-Hoffmann - peyerl@lrz.uni-muenchen.de; Nikolai Mühlberger - muelberger@bbges.de; Martin P Grobusch - martin.grobusch@uni-tuebingen.de; Joaquim Gascon - jgascon@clinic.ub.es; Alberto Matteelli - amatteelli@bsnet.it; Christoph Hatz - hutz@keep.touch.ch; Hermann Laferl - herman.laferl@kffj.magwien.gv.at; Marco Schulze - mhschulze@yahoo.com; Gerd Burchard - gerd.burchard@bni-hamburg.de; Saraiva da Cunha - saraiva@huc.min-saude.pt; Jiøi Beran - jiri.beran@vakcinace.cz; Paul McWhinney - pmcw@doctors.org.uk; Herwig Kollaritsch - herwig.kollaritsch@univie.ac.at; Peter Kern - peter.kern@medizin.uni-ulm.de; Juan Cuadros - jcuadros@efd.net; Michael Alifrangis - Malif@biobase.dk; Ida Gjørup - Ida.Gjorup@dadlnet.dk; the European Network on Surveillance of Imported Infectious Diseases (TropNetEurop).

* Corresponding author †Equal contributors

Published: 25 June 2003
Malaria Journal 2003, 2:17

Received: 06 May 2003
Accepted: 25 June 2003

This article is available from: http://www.malariajournal.com/content/2/1/17

© 2003 Wichmann et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: Malaria parasites that carry the DHFR-mutation I164L are not only highly resistant to sulfadoxine-pyrimethamine but also to the new antimalarial drug chlorproguanil-dapsone. The spread of this mutation in Africa would result in a public health disaster since there is a lack of effective alternatives that are both affordable and safe. Up to now, this mutation has only been described in Asian and Latin-American countries. The objective of this study was to assess the prevalence of this mutation in African isolates of *Plasmodium falciparum* that have been imported into Europe through travellers.
**Methods:** TropNetEurop is a network for the surveillance of travel-associated diseases and seems to cover approximately 12% of all malaria cases imported into Europe. Within this network we screened 277 imported African isolates of *P. falciparum* with the help of PCR- and enzyme-digestion-methods for the antifolate-resistant mutation I164L.

**Results:** The I164L mutation was not detected in any of the isolates tested.

**Discussion:** Continuous molecular surveillance of mutations in *P. falciparum*, as it is practised within TropNetEurop, is an essential tool for the understanding and early detection of the spread of antimalarial drug resistance in Africa.

**Background**
Drug resistant malaria is a major problem in malaria control. At the present, there are few antimalarial drugs available in endemic areas which are both cheap and save. Since resistance to chloroquine has spread across Sub-Saharan Africa, several countries have switched their first-line drug to the antifolate sulfadoxine-pyrimethamine [1].

Soon after sulfadoxine-pyrimethamine was introduced to malaria-control programs in the late 1960s, resistance to this drug was noted [2]. The efficacy of sulfadoxine-pyrimethamine primarily depends on the sensitivity of the parasite to pyrimethamine [3]. The dihydrofolate reductase domain of *Plasmodium falciparum* (pfDHFR) is the target of this drug. DHFR catalyzes the reduction of dihydrofolate to regenerate tetrahydrofolate which is required for one-carbon transfer reactions and deoxothymidylate synthesis of the parasites.

The discovery of changes in codons of the pfDHFR-gene strongly indicated that single amino acid changes lead to observed resistance. Mutations at amino acid position 51, 59, 108 and 164 have been shown to be linked with resistance of *P. falciparum* to antifolate antimalarials. A scheme for evolution of resistance could be derived as a result of stepwise mutations starting with the S108N mutation, which was shown to be the optimal mutation in leading to both the decreased binding affinity for inhibitors and the retention of enzyme activity [4,5]. Absolute resistance is conferred by the addition of I164L mutation in the quadruple mutant form (N108/I51/R59/L164). In this fourth mutation the enzyme is about 1,000-fold less sensitive to pyrimethamine [6].

The I164L mutation also plays an important role in the development of resistance to the more potent antifolate combination chlorproguanil-dapsone: while the triple mutant allele (N108/I51/R59) has no great impact on the sensitivity of this drug, parasites that carry the quadruple mutant allele are resistant [7,8]. This highly potent quadruple mutation was described first in South East Asia, later also in South America [9–11]. There is a concern that continued sulfadoxine-pyrimethamine pressure, as well as the widespread use of trimethoprim-sulfamethoxazole for prophylaxis against opportunistic infections in patients with AIDS in Africa, is going to select these highly resistant alleles [12]. This would rapidly make sulfadoxine-pyrimethamine, as well as chlorproguanil-dapsone, ineffective in this region. For this reason continued surveillance of this mutation is needed to evaluate the prevalence, the distribution and the speed with which these populations might be selected.

TropNetEurop is a European surveillance system that covers approximately 12% of all imported malaria cases in Europe [13]. Travellers can be used as a highly sensitive surveillance tool to detect development of drug-resistance in endemic areas, as it is suggested that most of them carry a monoclonal Plasmodium strain. Initial data on molecular surveillance, not including the I164L mutation, have already been published elsewhere [14].

Since there are only limited data available on the prevalence of the I164L mutation throughout Africa, the purpose of this survey was to screen a sample of *P. falciparum* imported from Africa for this particular antifolate mutation.

**Material and methods**

**Sampling**
The European Network on Imported Infectious Disease Surveillance (TropNetEurop) has been established in 1999 and, in 2001, covered approximately 12% of all imported malaria cases in Western and Central Europe [13]. At the present 45 clinical sites in Europe are members of the network with more than 57,000 patients seen post-travel annually.

Within the infrastructure of TropNetEurop several member sites started in 2001 to collect blood samples from patients diagnosed with a *P. falciparum* infection. 10 μl of whole blood from each patient were dotted on Whatman 3 MM® chromatography paper and air-dried at room temperature before initiation of treatment. The filter paper disks were sent to Munich for further preparation.
For this survey we screened all blood samples that were obtained between January 2001 and July 2002 from travellers returning from Africa with a microscopically confirmed *P. falciparum* infection.

**Parasite DNA and Polymerase chain reaction**
Parasite DNA was prepared from the dried blood spots on the filter paper by the Chelex method as described by Kain and Lanar [15]. Nested mutation-specific PCR was done as previously described for analysis of the DHFR 164 mutation site [16,17].

**Restriction fragment length polymorphisms**
A volume of 4 µl of PCR product was incubated for three hours at a temperature of 37°C with the mutation specific restriction enzyme Dral according to the manufacturer’s instructions (New England Biolabs, Beverly, MA, USA). To discriminate between the two variants of codon 164, the 522 bp PCR product was digested with Dral to detect the leucine mutation (143 bp). The digestion products were separated by electrophoresis in a 1% SeaKem™ plus 1% NuSieve™ gel (FMC BioProducts, Rockland, ME, USA) containing ethidium bromide. DNA from established laboratory strains of *P. falciparum* served as controls of PCR and enzyme digests. Gels were recorded by photography.

**Results**
Over the 18-month time period we collected 277 blood samples from patients with a microscopically confirmed *P. falciparum* infection acquired in Africa. The DNA from all blood samples was amplified by nested PCR systems as described above. 271 samples showed the expected bands at 522 bp for the DHFR gene, while six samples turned out to be negative for *P. falciparum* DNA.

Among the 271 observed samples of *P. falciparum*, 170 (62.7%) were imported from West Africa, 46 (16.6%) from East Africa, 36 (13%) from Central Africa, 17 (6.1%) from South Africa and two from Madagascar (Tab 1).

After digestion none of the 271 isolates revealed the leucine-164 mutation. All 271 isolates of *P. falciparum* presented as the wild type with the amino acid isoleucine in position 164.

**Discussion**
The burden of falciparum malaria is carried mainly by tropical Africa. Since resistance to Chloroquine is now widespread in Africa, the antifolate combination sulfadoxine-pyrimethamine (SP) is often the only affordable alternative.

Unfortunately, SP is particularly prone to the rapid emergence of resistance [18]. There is evidence, that in vitro pyrimethamine chemosensitivity will be predictive of in vivo SP efficacy, and that parasitological resistance in Africa is primarily due to the triple mutant in DHFR: S108N, N51I and C59R [19–21].

At the moment, the only drug available in Africa to deal with SP failure is often further treatment with SP. Researchers are, therefore, seeking new, safe and inexpensive, second line drugs or combination regimens. Among these regimes chlorproguanil-dapsone is considered a potential replacement for SP in Africa because of its effectiveness against infections associated with triple mutants in DHFR, its short half-life and its low price [21–23]. However, the efficacy of combinations involving old drugs may be short-lived, since resistance-conferring mutations already exist. In the case of chlorproguanil-dapsone, the change in DHFR enzyme structure resulting from the I164L mutation is known to be associated with resistance to this drug [19,20].

Experience with SP in South East Asia and South America has shown that continued use of SP will select for the quadruple mutant DHFR, including I164L. So far, mutations of this potency have not been observed in Africa in any study using standard PCR analyses [10,17,21,23–27]. The I164L mutation was also not found in any of the isolates we analyzed within this survey.

Recently, Hastings *et al.* [28] developed a yeast-based system that is sensitive enough to identify point mutations in

| Geographical Region     | Frequency (%) | Mutation (%) | Wild type (%) |
|-------------------------|---------------|--------------|---------------|
| West-Africa             | 170 (62.7)    | 0 (0%)       | 166 (100%)    |
| East-Africa             | 46 (16.6)     | 0 (0%)       | 46 (100%)     |
| Central-Africa          | 36 (13)       | 0 (0%)       | 36 (100%)     |
| South-Africa            | 17 (6.1)      | 0 (0%)       | 17 (100%)     |
| Madagascar              | 2 (0.7)       | 0 (0%)       | 2 (100%)      |
| Total                   | 271 (100)     | 0 (0%)       | 271 (100%)    |

PCR-negative 6
the DHFR gene even if they are rare. With the help of this technique alleles that encoded the I164L mutations were isolated from 3 of 6 patient samples with SP treatment failure from Tanzania. However, mutations of all kinds occur during DNA replication, but not all establish themselves and are functional.

Overall, efficient surveillance systems to detect and monitor resistance to SP are required, since malaria infections will become fully resistant to SP and chlorproguanil-dapsone with the selection of the DHFR mutation I164L in Africa. For this reason, several national and regional networks of sentinel sites have been set up in recent years and collaborate in order to monitor antimalarial drug resistance. The East African Network for Monitoring Antimalarial Treatment (EANMAT), for example, started in 1998 to monitor drug resistance with standard in vivo tests [29]. TropNetEurop, as the largest network for infectious diseases acquired by travellers worldwide, can function as an additional sensitive tool in the surveillance of antimalarial drug resistance.

Acknowledgements

We wish to thank all TropNetEurop site staff, who has been invaluable in collecting material and data. Financial support from Dr. Democh Maumeier Stiftung and the Förderprogramm für Forschung und Lehre der Medizinischen Fakultät, both at Ludwig-Maximilians-University, Munich, Germany, is gratefully acknowledged.

References

1. White NJ, Nosten F, Looareeesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molynieux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: Averting a malaria disaster Lancet 1999, 353:1965-1967.
2. Bjorkman A and Phillips-Howard PA: The epidemiology of drug-resistant malaria Trans R Soc Trop Med Hyg 1990, 84:177-180.
3. Sibley CH, Hyde JE, Sims PFG, Plowe CV, Kublin JG, Mberu EK, Cowie J and Phillips-Howard PA: Basis for antifolate action and resistance in malaria: The armoury, the problems and the prospects Sitol Today 2000, 16:146-153.
4. Peterson DS, Milhous WK and Wellems TE: Molecular basis of differential resistance to cycluguanil and pyrimethamine in Plasmodium falciparum Proc Nat Acad Sci USA 1990, 87:3018-22.
5. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
6. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
7. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
8. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
9. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
10. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
11. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
12. Plowe CV, Mberu EK, Watkins WM, Cortesec JF, Cajaado T, Marsh K, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruesболhik II TK, Danis M, Greenwood BM, Anderson RM and Olliaro P: In vivo and in vitro point mutations in the dihydrofolate reductase gene of Plasmodium falciparum in African isolates 1997, 79:1218-1223.
25. Eberl KJ, Jelinek T, Aida AO, Peyerl-Hoffmann G, Heuschkel C, el Valy AO and Christophel EM: Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of *Plasmodium falciparum* isolates from southern Mauritania. *Trop Med Int Health* 2001, 6:756-760.

26. Khalil I, Alifrangis M, Ronn AM, Gabar HA, Jelinek T, Satti GM and Bygbjerg IC: Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. *Am J Trop Med Hyg* 2002, 67:225-229.

27. Curtis J, Maxwell CA, Msuya FH, Mkongewa S, Allouche A and Warhurst DC: Mutations in *dhfr* in *Plasmodium falciparum* infections selected by chlorproguanil-dapsone treatment. *J Infect Dis* 2002, 186:1861-1864.

28. Hastings MD, Bates SJ, Blackstone EA, Mons SM, Mutabingwa TK and Sibley CH: Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of *Plasmodium falciparum* from Tanzania. *Trans R Soc Trop Med Hyg* 2002, 96:674-676.

29. Mutabingwa TK, Watkins WM and d’Alessandro U: Monitoring of drug-resistant malaria in Africa. *Lancet* 2002, 360:875.